Drug
Bgb 11417
Bgb 11417: highest development phase Phase 1, developed by BeiGene. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| BGB-11417 NCT04883957 | Phase 1 | Mature B-cell Malignancies |
Latest
No recent events.
Follow Bgb 11417 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.